Link between plasminogen activator inhibitor-1 and cardiovascular risk in chronic hepatitis C after viral clearance.

doi:10.1038/srep42503

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Link between plasminogen activator inhibitor-1 and cardiovascular risk in chronic hepatitis C after viral clearance.

Scientific reports - 13 Feb 2017

Chang Ming-Ling, Lin Yu-Sheng, Pao Li-Heng, Huang Hsin-Chih, Chiu Cheng-Tang

Abstract excerpt

The pathophysiological implications of plasminogen activator inhibitor-1 (PAI-1) in HCV infection remain obscure. This prospective study evaluated 669 HCV patients, of whom 536 had completed a course of anti-HCV therapy and had pre-, peri- and post-therapy measurements of various profiles, including PAI-1 levels. Multivariate analysis demonstrated, before anti-HCV-therapy, platelet count and PAI-1-rs1799889...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cardiovascular Diseases

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Plasminogen Activator Inhibitor 1

Share to Platelet Count

Share to RNA, Viral

Share to Viral Load

Source

Open in PubMed Open full text

Identifiers

PMID: 28211910
DOI: 10.1038/srep42503
PMCID: PMC5304196

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Link between plasminogen activator inhibitor-1 and cardiovascular risk in chronic hepatitis C after viral clearance.PMID 28211910Read ↗

Thrombophilic genetic factors PAI-1 4G-4G and MTHFR 677TT as risk factors of alcohol, cryptogenic liver cirrhosis and portal vein thrombosis, in a Caucasian population.Semantic proximity Read ↗

Serum PAI-1 and PAI-1 4G/5G Polymorphism in Hepatitis C Virus-Induced Cirrhosis and Hepatitis C Virus-Induced Hepatocellular Carcinoma Patients.Semantic proximity Read ↗

The effect of curing hepatitis C with direct-acting antiviral treatment on endothelial function.Semantic proximity Read ↗

Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment PerspectivesSemantic proximity Read ↗

Improvement of liver disease and inflammation in patients with advanced HCV-related cirrhosis after antiviral therapySemantic proximity Read ↗

Good or bad: Paradox of plasminogen activator inhibitor 1 (PAI-1) in digestive system tumorsSemantic proximity Read ↗

Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of EpigeneticsSemantic proximity Read ↗

Modulation of host lipid metabolism by hepatitis C virus: Role of new therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.